Evidence map›Paper›PMID 34668829›Full record

ArticleDrug delivery2021

Targeted delivery and stimulus-responsive release of anticancer drugs for efficient chemotherapy.

Lei Qiao, Xue Yuan, Hui Peng, Guisong Shan, Min Gao, Xiaoqing Yi, Xiaoyan He

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Drug delivery, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.6field-weighted citation impact, top 36% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 8 citations in OpenAlex.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 3 institutions in 1 country.

Lei QiaoSchool of Basic Medical Sciences, Anhui Medical University, Hefei, China.
Xue YuanInflammation and Immune Mediated Diseases Laboratory of Anhui Province, School of Life Sciences, Anhui Medical University, Hefei, China.
Hui PengInflammation and Immune Mediated Diseases Laboratory of Anhui Province, School of Life Sciences, Anhui Medical University, Hefei, China.
Guisong ShanInflammation and Immune Mediated Diseases Laboratory of Anhui Province, School of Life Sciences, Anhui Medical University, Hefei, China.
Min GaoDepartment of Respiratory and Critical Care Medicine, The First Affiliated Hospital of Anhui Medical University, Hefei, China.
Xiaoqing YiKey Laboratory of Prevention and Treatment of Cardiovascular and Cerebrovascular Diseases, Ministry of Education, Gannan Medical University, Ganzhou, China.
Xiaoyan HeInflammation and Immune Mediated Diseases Laboratory of Anhui Province, School of Life Sciences, Anhui Medical University, Hefei, China.
Anhui Medical University · CNFirst Affiliated Hospital of Anhui Medical University · CNGannan Medical University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Chemotherapy is currently an irreplaceable strategy for cancer treatment. Doxorubicin hydrochloride (DOX) is a clinical first-line drug for cancer chemotherapy. While its efficacy for cancer treatment is greatly compromised due to invalid enrichment or serious side effects. To increase the content of intracellular targets and boost the antitumor effect of DOX, a novel biotinylated hyaluronic acid-guided dual-functionalized CaCO

Indexed as

AnimalsAntineoplastic AgentsApoptosisCell Line, TumorCell SurvivalChemistry, PharmaceuticalDose-Response Relationship, DrugDoxorubicinDrug CarriersDrug LiberationHyaluronic AcidHydrogen-Ion ConcentrationMembrane Potential, MitochondrialMiceNanoparticlesXenograft Model Antitumor AssaysAntineoplastic AgentsDoxorubicinDrug CarriersHyaluronic Acidacid-responseCaCO3Chemotherapymitochondrianucleustargeted delivery

Identifiers

PMID34668829
PMCPMC8530493
OpenAlexW3205198618

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.